Antibody-Mediated Encephalitis
NEJM 378:840-851, Dalmau, J.,et al, 2018
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
NMDA Receptor Encephalitis Mimicking Seronegative Neuromyelitis Optica
Neurol 74:1473-1475, Kruer,M.C., et al, 2010
Neurologic Manifestations and Outcome of West Nile Virus Infection
JAMA 290:511-515,524,558, Sejvar,J.J.,et al, 2003
Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinsons Disease
NEJM 388:683-693, 759, Krishna,V.,et al, 2023
Clnicopathologic Conference Anti-N-Methyl-D-Aspartate (NMDA) Receptor Encephalitis
NEJM 379:870-878, CASE 27-2018, 2018
Paraneoplastic and Autoimmune Encephalitis
UptoDate July, Dalmau, J.,et al, 2017
Withdrawing Amantadine in Dyskinetic Patients with Parkinson Disease
Neurol 82:300-307, Ory-Magne, F.,et al, 2014
Long-Term Safety and Tolerability of ProSavin, a Lentiviral Vector-Based Gene Therapy for Parkinsons Disease: A Dose Escalation, Open-Label, Phase 1/2 Trial
Lancet 383:1138-1146,1107, Palfi, S.,et al, 2014
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Antipsychosis Drugs
Adams & Victors Principles of Neurology Chp 43, pg 1208, Ropper, A.H.,et al, 2014
Deep-Brain Stimulation for Parkinsons Disease
NEJM 367:1529-1538, Okon, M.S., 2012
Late onset autism and anti-NMDA-receptor encephalitis
Lancet 378:98;378, Creten, C.,et al, 2011
Response to Immunotherapy in a 20-Month-Old Boy With Anti-NMDA Receptor Encephalitis
Neurol 74:1550-1551, Wong-Kisiel,L.C., et al, 2010
Absence Epilepsies With Widely Variable Onset are a Key Feature of Familial GLUT1 Deficiency
Neurol 75:432-440, Mullen,S.A., et al, 2010
Retrospective Analysis of NMDA Receptor Antibodies in Encephalitis of Unknown Origin
Neurol 75:1735-1739, Pr�ss,H.,et al, 2010
Anti-N-Methyl-D-Aspartate Receptor (NHMDAR) Encephalitis in Children and Adolescents
Ann Neurol 66:11-18,1, Florance,N.R.,et al, 2009
N-Methyl-D-Aspartate Receptor Antibodies in Pediatric Dyskinetic Encephalitis Lethargica
Ann Neurol 66:704-709, Dale,R.,et al, 2009
Anti-NMDA-Receptor Encephalitis: Case Series and Analysis of the Effects of Antibodies
Lancet Neurol 7:1091-1098, Dalmau,J.,et al, 2008
Anti-NMDA-Receptor Encephalitis: Case Series and Analysis of the Effects of Antibodies
Lancet Neurol 7:1091-1098, Dalmau,J.,et al, 2008
Diffusion-Weighted Magnetic Resonance Imaging in the Syndrome of Acute Bilateral Basal Ganglia Lesions in Diabetic Uremia
Mov Disord 21:1267-1270, Kim, T.,et al, 2006
Etiological and Therapeutical Observations in a Case of Belly Dancers Dyskinesia
Movement Disorders 20:251-253, Linazasoro,G., et al, 2005
Treatments of Parkinson Disease
Arch Neurol 60:1680-1684, Shults,C.W., 2003
Subthalamic DBS Replaces Levodopa in Parkinson's Disease
Neurol 58:396-401, Vingerhoets,F.J.G.,et al, 2002
Cocaine-Induced Persistent Dyskinesias
Neurol 56:964-965, Weiner,W.J.,et al, 2001
A Five-Year Study of the Incidence of Dyskinesia in Patients With Early Parkinson's Disease who were Treated with Ropinirole or Levodopa
NEJM 342:1484-1491, Rascol,O.,et al, 2000
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease
JAMA 284:1931-1938,1971, Parkinson Study Group, 2000
Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999
Stereotactic pallidotomy for Trtm of Parkinson's Disease, Efficacy & Adverse Effects at 6 Mo in 26 Pts
Neurol 50:434-438, Shannon,K.M.,et al, 1998
Tardive Dyskinesia:Diagnosis, Pathogenesis, and Management
The Neurologist 4:180-187, Trugman,J.M., 1998
Catechol-O-Methyltransferase Inhibitors for Treatment of Parkinson's Disease
Lancet 351:1221-1222, Nutt,J.G., 1998
Dystonia and Chorea in Acquired Systemic Disorders
JNNP 65:436-445, Janavs,J.L.&Aminoff,M.J., 1998
Low-Dose Clozapine Improves Dyskinesias in Parkinson's Disease
Neurol 48:658-662, Durif,F.,et al, 1997
Tolcapone Improves Motor Function in Parkinsonian Pts with the"Wearing Off"Phenomenon
Neurol 49:1066-1071, Rajput,A.H.,et al, 1997
Choreoathetotic Movements:A Possible Side Effect of Gabapentin
Neurol 46:851-852, Buetefisch,C.M.,et al, 1996
Drug Treatment of Parkinson's Disease
BMJ 310:575-579, Quinn,N., 1995
Cocaine-Induced Choreoathetoid Movements ('Crack Dancing')
Neurol 44:751-752, Daras,M.,et al, 1994
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Tardive Stereotype and Other Movement Disorders in Tardive Dyskinesias
Neurol 43:937-941, Stacy,M.,et al, 1993
Tardive Dyskinesia Associated with Use of Metoclopramide in a Child
J Pediatr 121:983-985, Putnam,P.E.,et al, 1992
Early Development of Levodopa-Induced Dyskinesias and Response Fluctuations in Young-Onset Parkinson's Disease
Neurol 41:202-205, Kostic,V., 1991
Movement Disorders in Alcoholism:A Review
Neurol 40:741-746, Neiman,J.,et al, 1990
Levodopa-Induced Dyskinesia:Review, Observations, and Speculations
Neurol 40:340-345, Nutt,J.G., 1990
Unusual Neurotoxicity Associated with Amiodarone Therapy
Arch Int Med 147:881-884, Palakurthy,P.R.,et al, 1987
Extrapyramidal Reactions with Metoclopramide
BMJ 291:930-932, Bateman,D.N.,et al, 1985
Phenobarbital-Induced Dyskinesia in a Neurologically Impaired Child
Neurol 34:1600-1601, Wiznitzer,M.,et al, 1984
Metoclopramide & Tardive Dyskinesia in the Elderly
BMJ 289:397-398, Orme,M.L., 1984
Depression-Dependent Dyskinesias In Two Cases Of Manic-Depressive Illness
NEJM 304:1088-1089, Cutler,N.R.,et al, 1981
Onset & End-of-dose Levodopa-induced Dyskinesias
Arch Neurol 35:261, Lhermitte,F.,et al, 1978
Anticonvulsant-induced Dyskinesias:A Comparison with Dyskinesias Induced by Neuroleptics
JNNP 39:1210, Chadwick,D.,et al, 1976